KSHN 001075
Alternative Names: KSHN-001075Latest Information Update: 29 Jul 2021
At a glance
- Originator Kashiv BioSciences
- Class Antineoplastics; Estradiol congeners; Estrenes; Fluorinated hydrocarbons; Sulfoxides
- Mechanism of Action Estrogen receptor antagonists; Selective estrogen receptor degraders
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Breast cancer
Most Recent Events
- 21 Jul 2021 KSHN 001075 is available for licensing as of 21 Jul 2021. https://kashivbiosciences.com/company-overview/
- 04 Jun 2021 Preclinical trials in Breast cancer in India (PO)
- 04 Jun 2021 Pharmacodynamics and pharmacokinetics data from a preclinical trial in Breast cancer presented at the 57th Annual Meeting of the American Society of Clinical Oncology (ASCO-2021)